OBJECTIVES: This study examines the tolerability and efficacy of methylphenidate (MPH) and behavior modification therapy (BMOD) in children with attention-deficity/hyperactivity disorder (ADHD) and severe mood dysregulation (SMD). METHODS:Children (ages 5-12) from a summer program for ADHD were screened forSMD and additional manic-like symptoms using structured assessments and direct clinical interview with the Young Mania Rating Scale (YMRS). The SMD group was comprised of 33 subjects with SMD and elevated YMRS scores (mean = 23.7). They underwent weekly mood assessments plus the daily ADHD measures that are part of the program. The comparison group (n = 68) was comprised of the rest of the program participants. Using a crossover design, all subjects in both groups were treated with three varying intensities of BMOD (no, low, high) each lasting 3 weeks, with MPH dose (placebo, 0.15 mg/kg t.i.d., 0.3mg/kg t.i.d., and 0.6 mg/kg t.i.d.) varying daily within each behavioral treatment. RESULTS: Groups had comparable ADHD symptoms at baseline, with the SMD group manifesting more oppositional defiant disorder/conduct disorder (ODD/CD) symptoms (p < 0.001). Both groups showed robust improvement in externalizing symptoms (p < 0.001). There was no evidence of differential treatment efficacy or tolerability. Treatment produced a 34% reduction in YMRS ratings in SMD subjects (p - 0.001). However, they still exhibited elevated YMRS ratings, more ODD/CD symptoms (p < 0.001), and were more likely to remain significantly impaired at home than non-SMD subjects (p < 0.05). CONCLUSIONS: MPH and BMOD are tolerable and effective treatments for children with ADHD and SMD, but additional treatments may be needed to optimize their functioning.
RCT Entities:
OBJECTIVES: This study examines the tolerability and efficacy of methylphenidate (MPH) and behavior modification therapy (BMOD) in children with attention-deficity/hyperactivity disorder (ADHD) and severe mood dysregulation (SMD). METHODS:Children (ages 5-12) from a summer program for ADHD were screened for SMD and additional manic-like symptoms using structured assessments and direct clinical interview with the Young Mania Rating Scale (YMRS). The SMD group was comprised of 33 subjects with SMD and elevated YMRS scores (mean = 23.7). They underwent weekly mood assessments plus the daily ADHD measures that are part of the program. The comparison group (n = 68) was comprised of the rest of the program participants. Using a crossover design, all subjects in both groups were treated with three varying intensities of BMOD (no, low, high) each lasting 3 weeks, with MPH dose (placebo, 0.15 mg/kg t.i.d., 0.3mg/kg t.i.d., and 0.6 mg/kg t.i.d.) varying daily within each behavioral treatment. RESULTS: Groups had comparable ADHD symptoms at baseline, with the SMD group manifesting more oppositional defiant disorder/conduct disorder (ODD/CD) symptoms (p < 0.001). Both groups showed robust improvement in externalizing symptoms (p < 0.001). There was no evidence of differential treatment efficacy or tolerability. Treatment produced a 34% reduction in YMRS ratings in SMD subjects (p - 0.001). However, they still exhibited elevated YMRS ratings, more ODD/CD symptoms (p < 0.001), and were more likely to remain significantly impaired at home than non-SMD subjects (p < 0.05). CONCLUSIONS: MPH and BMOD are tolerable and effective treatments for children with ADHD and SMD, but additional treatments may be needed to optimize their functioning.
Authors: J Biederman; E Mick; J Prince; J Q Bostic; T E Wilens; T Spencer; J Wozniak; S V Faraone Journal: J Child Adolesc Psychopharmacol Date: 1999 Impact factor: 2.576
Authors: Melissa A Brotman; Layla Kassem; Michelle M Reising; Amanda E Guyer; Daniel P Dickstein; Brendan A Rich; Kenneth E Towbin; Daniel S Pine; Francis J McMahon; Ellen Leibenluft Journal: Am J Psychiatry Date: 2007-08 Impact factor: 18.112
Authors: Amanda E Guyer; Erin B McClure; Abby D Adler; Melissa A Brotman; Brendan A Rich; Alane S Kimes; Daniel S Pine; Monique Ernst; Ellen Leibenluft Journal: J Child Psychol Psychiatry Date: 2007-09 Impact factor: 8.982
Authors: Daniel S Pine; Amanda E Guyer; Michelle Goldwin; Kenneth A Towbin; Ellen Leibenluft Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-06 Impact factor: 8.829
Authors: Boris Birmaher; David Brent; William Bernet; Oscar Bukstein; Heather Walter; R Scott Benson; Allan Chrisman; Tiffany Farchione; Laurence Greenhill; John Hamilton; Helene Keable; Joan Kinlan; Ulrich Schoettle; Saundra Stock; Kristin Kroeger Ptakowski; Jennifer Medicus Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-11 Impact factor: 8.829
Authors: Robert L Findling; Elizabeth J Short; Nora K McNamara; Christine A Demeter; Robert J Stansbrey; Barbara L Gracious; Resaca Whipkey; Michael J Manos; Joseph R Calabrese Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-11 Impact factor: 8.829
Authors: Leslie Miller; Stefanie A Hlastala; Laura Mufson; Ellen Leibenluft; Mark Riddle Journal: Evid Based Pract Child Adolesc Ment Health Date: 2016-11-14
Authors: James G Waxmonsky; Daniel A Waschbusch; Peter Belin; Tan Li; Lysett Babocsai; Hugh Humphery; Meaghan E Pariseau; Dara E Babinski; Martin T Hoffman; Jenifer L Haak; Jessica R Mazzant; Gregory A Fabiano; Jeremy W Pettit; Negar Fallahazad; William E Pelham Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-12-28 Impact factor: 8.829
Authors: James G Waxmonsky; Fran A Wymbs; Meaghan E Pariseau; Peter J Belin; Daniel A Waschbusch; Lysett Babocsai; Gregory A Fabiano; Opeolowa O Akinnusi; Jenifer L Haak; William E Pelham Journal: J Atten Disord Date: 2012-02-28 Impact factor: 3.256
Authors: Tiffany A Greenwood; Eun-Jeong Joo; Tatyana Shekhtman; A Dessa Sadovnick; Ronald A Remick; Paul E Keck; Susan L McElroy; John R Kelsoe Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-12-19 Impact factor: 3.568
Authors: Susan D Mayes; James D Waxmonsky; Susan L Calhoun; Edward O Bixler Journal: J Child Adolesc Psychopharmacol Date: 2016-01-08 Impact factor: 2.576